TABLE: In turbulent week, 2 IPOs price, 6 test waters
This article was originally published in Scrip
While the biotechnology industry continues to debate whether the window for initial public offerings is closing, two drug developers priced IPOs during a US stock trading week shortened by the July 4th holiday and six revealed their plans to become public companies.
You may also be interested in...
Intellia Therapeutics Inc. sold more shares in its initial public offering than originally expected and the CRISPR/Cas9 specialist did so at the top of its proposed price range, proving that investors remain excited about gene editing, but have less enthusiasm for other early-stage therapeutics firms.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.